{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:11:02Z","timestamp":1793293862511,"version":"4.5.0"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"\n Importance<\/jats:title>\n The dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) agonist tirzepatide was noninferior to a GLP-1 agonist, dulaglutide, for effects on the composite outcome of cardiovascular death, myocardial infarction (MI), or stroke. However, comparison for a comprehensive range of major adverse cardiovascular and kidney outcomes has not been reported.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To perform a post hoc analysis for an expanded range of adverse outcomes in a completed randomized clinical trial comparing the effects of tirzepatide and dulaglutide in patients with type 2 diabetes and cardiovascular disease.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This parallel-design double-blind trial enrolled patients with diabetes and preexisting cardiovascular disease (from May 29, 2020, to June 27, 2022) at 640 centers in North and South America, Europe, Asia, and Oceania. Data were analyzed from July 2025 to February 2026.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomized to receive subcutaneous tirzepatide up to 15 mg (n\u2009=\u20096586) or a fixed dose of dulaglutide, 1.5 mg (n\u2009=\u20096579), administered weekly.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary efficacy measure was time from randomization to first occurrence of a 6-component composite of cardiorenal adverse outcomes, including all-cause mortality, MI, stroke, coronary revascularization, hospitalization for heart failure, and a composite of adverse kidney outcomes.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among the 13\u202f165 patients enrolled, the mean (SD) age was 64 (8.8) years; 9348 patients (71.0%) were male and 3817 were female (29.0%). The mean (SD) hemoglobin A\n 1c<\/jats:sub>\n was 8.4% (0.93). After a median (IQR) treatment duration of 46.9 (34.6-50.6) months, the primary cardiorenal end point occurred in 1559 tirzepatide-treated patients (23.7%) and 1803 dulaglutide-treated patients (27.4%; hazard ratio [HR], 0.84; 95% CI, 0.79-0.90;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Sensitivity analyses showed similar hazard ratios for a narrower 5-component end point (without the kidney composite outcomes: HR, 0.86; 95% CI, 0.80-0.93) and the 4-component composite (without either kidney or heart failure end points: HR, 0.86; 95% CI, 0.80-0.93). Gastrointestinal adverse events were more common with tirzepatide (2827 patients [42.5%]) than dulaglutide (2387 patients [35.9%]) treatment. Other adverse events were similar.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In this post hoc analysis, the dual GLP-1 and GIP agonist tirzepatide, compared with the GLP-1 agonist dulaglutide, was associated with a lower incidence of a broad 6-component composite cardiovascular and kidney end point in patients with diabetes and established cardiovascular disease.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04255433<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamacardio.2026.0767","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T19:30:19Z","timestamp":1774726219000},"page":"544","source":"Crossref","is-referenced-by-count":24,"title":["Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease"],"prefix":"10.1001","volume":"11","author":[{"given":"Steven E.","family":"Nissen","sequence":"first","affiliation":[{"name":"Cleveland Clinic Coordinating Center for Clinical Research (C5 Research), Cleveland Clinic, Cleveland, Ohio"},{"name":"Department of Medicine, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Wolski","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Coordinating Center for Clinical Research (C5 Research), Cleveland Clinic, Cleveland, Ohio"},{"name":"Department of Medicine, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D\u2019Alessio","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govinda","family":"Weerakkody","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Kiljanski","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell J.","family":"Wiese","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imre","family":"Pavo","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[{"name":"l\u2019Institut du Thorax, Nantes Universite, CHU Nantes, CNRS, INSERM, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Victorian Heart Institute, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"hoi260015r1","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention.","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"hoi260015r2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity.","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"hoi260015r3","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes.","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"hoi260015r4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes.","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"19","key":"hoi260015r5","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1136\/heartjnl-2024-324170","article-title":"Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial.","volume":"110","author":"Krumholz","year":"2024","journal-title":"Heart"},{"issue":"12","key":"hoi260015r6","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1111\/dom.15272","article-title":"Effect of tirzepatide on blood pressure and lipids: a meta-analysis of randomized controlled trials.","volume":"25","author":"Kanbay","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"hoi260015r7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"hoi260015r8","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10193","key":"hoi260015r9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"10157","key":"hoi260015r10","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"20","key":"hoi260015r11","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes.","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"hoi260015r12","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s42255-023-00812-z","article-title":"Gut hormone co-agonists for the treatment of obesity: from bench to bedside.","volume":"5","author":"Nogueiras","year":"2023","journal-title":"Nat Metab"},{"key":"hoi260015r13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.","volume":"267","author":"Nicholls","year":"2024","journal-title":"Am Heart J"},{"issue":"24","key":"hoi260015r14","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes.","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"issue":"20","key":"hoi260015r15","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association.","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"24","key":"hoi260015r16","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes.","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"hoi260015r17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity.","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"hoi260015r18","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"hoi260015r19","doi-asserted-by":"publisher","first-page":"846","DOI":"10.2337\/dc25-0241","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials.","volume":"48","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"issue":"1","key":"hoi260015r20","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa545","article-title":"The association between body mass index and the risk of hospitalization and mortality due to infection: a prospective cohort study.","volume":"8","author":"Yang","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"hoi260015r21","doi-asserted-by":"publisher","first-page":"j477","DOI":"10.1136\/bmj.j477","article-title":"Adiposity and cancer at major anatomical sites: umbrella review of the literature.","volume":"356","author":"Kyrgiou","year":"2017","journal-title":"BMJ"},{"issue":"13","key":"hoi260015r22","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2019.14231","article-title":"Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity.","volume":"322","author":"Aminian","year":"2019","journal-title":"JAMA"},{"issue":"9","key":"hoi260015r23","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1002\/oby.24332","article-title":"Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial.","volume":"33","author":"Lam","year":"2025","journal-title":"Obesity (Silver Spring)"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2847048\/jamacardiology_nissen_2026_oi_260015_1780929855.50022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:00:44Z","timestamp":1781103644000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2847048"}},"subtitle":["A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2026.0767","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}